TrialJournal of cancer research and clinical oncology2017

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib.

Markus Pfirrmann et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.